Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Cash from Investing Activities (2021 - 2025)

Krystal Biotech's Cash from Investing Activities history spans 5 years, with the latest figure at $11.2 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 113.32% year-over-year to $11.2 million; the TTM value through Dec 2025 reached -$58.4 million, up 64.26%, while the annual FY2025 figure was -$58.4 million, 64.26% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was $11.2 million at Krystal Biotech, up from -$4.3 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $105.2 million in Q3 2023 and bottomed at -$126.5 million in Q4 2021.
  • The 5-year median for Cash from Investing Activities is -$17.7 million (2023), against an average of -$24.0 million.
  • The largest annual shift saw Cash from Investing Activities tumbled 7384.34% in 2022 before it soared 813.5% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at -$126.5 million in 2021, then skyrocketed by 95.88% to -$5.2 million in 2022, then tumbled by 95.08% to -$10.2 million in 2023, then plummeted by 724.59% to -$83.8 million in 2024, then surged by 113.32% to $11.2 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Cash from Investing Activities are $11.2 million (Q4 2025), -$4.3 million (Q3 2025), and -$10.5 million (Q2 2025).